版本:
中国

BRIEF-CASI Pharmaceuticals reports on enrollment status of ENMD-2076 phase 2 study in triple-negative breast cancer

April 14 Casi Pharmaceuticals Inc

* Says decision has been reached to stop further patient enrollment in its phase 2, open-label study of enmd-2076

* Company continues to collect and evaluate data in those patients enrolled in study

* Says biomarker program which evaluates potential markers that could be predictive of a response to enmd-2076 is ongoing

* Says ongoing phase 2a study in china in patients with tnbc continues Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐